Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Sep 18;193(4):591.
doi: 10.1093/bjd/ljaf265.

Rigosertib as a potential therapeutic option for patients with recessive dystrophic epidermolysis bullosa squamous cell carcinoma

Affiliations
Editorial

Rigosertib as a potential therapeutic option for patients with recessive dystrophic epidermolysis bullosa squamous cell carcinoma

John J G Pritchard et al. Br J Dermatol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare they have no conflicts of interest.

Comment on

References

    1. Eichstadt S, Tang JY, Solis DC et al. From clinical phenotype to genotypic modelling: incidence and prevalence of recessive dystrophic epidermolysis bullosa (RDEB). Clin Cosmet Investig Dermatol 2019; 12:933–42 - PMC - PubMed
    1. Robertson SJ, Orrin E, Lakhan MK et al. Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study. Acta Derm Venereol 2021; 101:adv00523. - PMC - PubMed
    1. Hwang A, Kwon A, Miller CH, et al. Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases. Orphanet J Rare Dis 2024; 19:206. - PMC - PubMed
    1. Laimer M, South AP, Mayr E et al. Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa associated advanced/metastatic cutaneous squamous cell carcinoma. Br J Dermatol 2025; 193:758–66. - PubMed
    1. Watt, SA, Pourreyron C, Puride K et al. Integrative mRNA profiling comparing cultured primary cells with clinical samples reveals PLK1 and C20orf20 as therapeutic targets in cutaneous squamous cell carcinoma. Oncogene 2011; 30:4666–77. - PMC - PubMed

LinkOut - more resources